Overcoming the neuroleptic‐induced deficit syndrome: clinical observations with remoxipride
Author:
- 1 May 1994
- journal article
- review article
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 89 (s380) , 64-67
Abstract
Remoxipride is a selective dopamine D2 antagonist with virtually no activity on other transmitter receptors. It antagonizes dopamine agonists within a wide dose range in animals when it does not cause sedation or akinesia. Clinical studies with remoxipride have demonstrated antipsychotic efficacy apparently equal to classical neuroleptics in short- and long-term treatment of schizophrenia. Remoxipride has a low extrapyramidal syndrome (EPS) profile, and it is generally well tolerated. In clinical practice remoxipride has been reported to differ from classical neuroleptics with regard to subjective side effects. On switching to remoxipride, patients report improvement in cognitive, conative, affective and emotional functions. In many cases the reports are supported by family members and/or caregivers. Although anecdotal, such reports are in line with the low EPS profile of remoxipride and its weak sedative properties. It may indicate that remoxipride does not elicit the neuroleptic-induced deficit syndrome, commonly experienced with classical neuroleptics, or that remoxipride improves the deficit syndrome (or primary negative symptoms) of schizophrenia. These and other hypotheses need to be confirmed by formal clinical studies.Keywords
This publication has 30 references indexed in Scilit:
- Antideficit properties of neurolepticsActa Psychiatrica Scandinavica, 1994
- Remoxipride therapy in treatment resistant schizophreniaSchizophrenia Research, 1993
- RemoxiprideDrugs, 1990
- Experiences of long‐term treatment with remoxipride: efficacy and tolerabilityActa Psychiatrica Scandinavica, 1990
- A placebo‐controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbationActa Psychiatrica Scandinavica, 1990
- Safety evaluation in both short‐ and long‐term treatment of schizophrenia with remoxiprideActa Psychiatrica Scandinavica, 1990
- The effect of long‐term treatment with clozapine in schizophrenia: A retrospective study in 96 patients treated with clozapine for up to 13 yearsActa Psychiatrica Scandinavica, 1988
- Objective and subjective effects of remoxipride, alone and in combination with ethanol or diazepam, on performance in healthy subjectsJournal of Psychopharmacology, 1988
- Antipsychotic withdrawal symptoms: Phenomenology and pathophysiologyActa Psychiatrica Scandinavica, 1988
- Clinical Evaluation of Sulpiride in Schizophrenic Patients ‐ A Double‐blind Comparison with ChlorpromazineActa Psychiatrica Scandinavica, 1984